The email correspondent has been marked as private and confidential (what don't you know about private and confidential) but in all honesty, I thought you holders would know what clinical trial data did Wheezo received regulatory approval was tested against, the AGM 2019 presentation indicated it was against just the stethoscope and RSH are now planning to test it against the current clinician standard which was meant to be completed by April 2020????
Respiri investor Presentation, page-75
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.80M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 95363 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 199999 | 1 |
View Market Depth
| Last trade - 16.12pm 01/07/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable